Traws Pharma Past Earnings Performance
Past criteria checks 0/6
Traws Pharma has been growing earnings at an average annual rate of 4.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 51% per year.
Key information
4.1%
Earnings growth rate
83.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -51.0% |
Return on equity | -177.5% |
Net Margin | -8,384.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Onconova Therapeutics names Mark Gelder as chief medical officer
Jun 01Onconova Therapeutics announces $8.7M registered direct offering
Jan 07Onconova cleared to start Phase 1 trial for cancer therapy
Dec 24Onconova Therapeutics EPS in-line, misses on revenue
Nov 12Revenue & Expenses BreakdownBeta
How Traws Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -19 | 9 | 11 |
30 Sep 23 | 0 | -20 | 9 | 13 |
30 Jun 23 | 0 | -21 | 8 | 14 |
31 Mar 23 | 0 | -21 | 8 | 13 |
31 Dec 22 | 0 | -19 | 8 | 11 |
30 Sep 22 | 0 | -17 | 9 | 9 |
30 Jun 22 | 0 | -15 | 9 | 8 |
31 Mar 22 | 0 | -16 | 9 | 7 |
31 Dec 21 | 0 | -16 | 9 | 7 |
30 Sep 21 | 0 | -19 | 9 | 10 |
30 Jun 21 | 0 | -22 | 9 | 13 |
31 Mar 21 | 0 | -25 | 9 | 15 |
31 Dec 20 | 0 | -25 | 8 | 17 |
30 Sep 20 | 0 | -24 | 8 | 16 |
30 Jun 20 | 0 | -23 | 8 | 16 |
31 Mar 20 | 2 | -19 | 7 | 15 |
31 Dec 19 | 2 | -22 | 7 | 15 |
30 Sep 19 | 2 | -21 | 7 | 16 |
30 Jun 19 | 2 | -22 | 7 | 16 |
31 Mar 19 | 1 | -23 | 7 | 16 |
31 Dec 18 | 1 | -21 | 8 | 17 |
30 Sep 18 | 1 | -21 | 7 | 17 |
30 Jun 18 | 1 | -23 | 7 | 18 |
31 Mar 18 | 1 | -21 | 7 | 19 |
31 Dec 17 | 1 | -24 | 7 | 19 |
30 Sep 17 | 1 | -23 | 8 | 21 |
30 Jun 17 | 2 | -18 | 9 | 19 |
31 Mar 17 | 4 | -21 | 8 | 19 |
31 Dec 16 | 6 | -20 | 9 | 20 |
30 Sep 16 | 15 | -11 | 8 | 19 |
30 Jun 16 | 15 | -15 | 8 | 20 |
31 Mar 16 | 13 | -19 | 10 | 22 |
31 Dec 15 | 11 | -24 | 10 | 26 |
30 Sep 15 | 2 | -41 | 11 | 32 |
30 Jun 15 | 0 | -50 | 12 | 38 |
31 Mar 15 | 0 | -57 | 13 | 45 |
31 Dec 14 | 1 | -64 | 15 | 49 |
30 Sep 14 | 3 | -65 | 16 | 51 |
30 Jun 14 | 4 | -71 | 19 | 55 |
31 Mar 14 | 4 | -68 | 18 | 52 |
31 Dec 13 | 5 | -65 | 17 | 50 |
30 Sep 13 | 6 | -62 | 15 | 49 |
30 Jun 13 | 47 | -43 | 18 | 60 |
Quality Earnings: TRAW is currently unprofitable.
Growing Profit Margin: TRAW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRAW is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare TRAW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRAW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: TRAW has a negative Return on Equity (-177.55%), as it is currently unprofitable.